Vijaya Diagnostic Centre Ltd.
NSE: VIJAYAVijaya Diagnostic Centre Ltd.: A 30-second snapshot
Vijaya Diagnostic Centre (VIJAYA) trades at ₹1,329, up 34.6% over 12 months and 31% over the past 3 months, sitting 30% above its 200-day moving average with RSI at 76. Trailing PE of 80.2 is the highest among 6 tracked peers; forward PE of 51.3 reflects market expectations of continued earnings growth, supported by FY26 revenue rising 26.6% year-on-year. The D/E ratio of 42.22 is the most structurally unusual metric for a diagnostics operator, and the debt trend is rising.
P/E
80.2
Forward P/E
51.3
ROE
—
Debt / Equity
42.22
Profit Margin
+20.7%
Div. Yield
+0.2%
5Y ROE > 15%
4/5
5Y FCF > 0
4/5
Quality
64/100
News
8 headlines · 4 positive · 0 negative
Vijaya Diagnostic FY26 Revenue Rises 26.6% - scanx.trade
scanx.trade
Vijaya Diagnostic Centre Shareholders Approve Two Independent Directors via Postal Ballot - scanx.trade
scanx.trade
Vijaya Diagnostics Board Strengthened with Two New Independent Directors - Whalesbook
Whalesbook
Vijaya Diagnostic Centre Recommends Dividend Of 2 Rupees/Share - TradingView
TradingView
Vijaya Diagnostic Centre Schedules Analyst and Institutional Investor Meetings on May 20-21, 2026 - scanx.trade
scanx.trade
Recent context
- ·FY26 full-year revenue rose 26.6% according to a May 2026 disclosure, sustaining the multi-year growth trajectory reported in the 5-year fundamental data.
- ·The board added two independent directors via postal ballot in May 2026, and analyst and institutional investor meetings are scheduled for 20–21 May 2026, suggesting active investor-relations engagement around the results period.
- ·A ₹2/share dividend was recommended by the board in May 2026; at a current price of ₹1,329, the implied yield is approximately 0.15%, in line with the reported 0.17% dividend yield in the fundamental data.
Strengths
- +5-year revenue CAGR of 21.4% and earnings CAGR of 22.5% reflect consistent top- and bottom-line compounding over the measured period.
- +FCF was positive in 4 of the available fiscal years, and the persistence consistency score of 83 ranks highest among the 6-peer sector group on quality score (57 vs nearest peer Max Healthcare at 54).
- +Profit margin of 20.73% is a meaningful absolute level for a healthcare services operator, indicating pricing power or cost discipline relative to revenue.
- +FY26 revenue growth of 26.6% (per May 2026 disclosure) and a ₹2/share dividend recommendation signal operational momentum continuing into the current fiscal year.
Weaknesses
- −D/E of 42.22 with a rising debt trend is materially out of line with a non-lending diagnostics business; leverage at this level amplifies downside in any revenue or margin stress scenario.
- −Trailing PE of 80.24 is the most expensive valuation in the 6-stock peer group; the stock has priced in substantial forward earnings delivery, leaving limited margin for an earnings shortfall.
- −RSI at 76.19 with price 30% above SMA200 and no identified resistance levels above ₹1,329 flags the stock as extended relative to its own recent price history.
- −Nearest support levels are at ₹944, ₹918, and ₹848 — a gap of 29–36% below current price — indicating that a reversion to recent technical support would represent a significant move.
Open questions
- ?Does the D/E of 42.22 reflect operating lease capitalisation (common in diagnostics post Ind AS 116) or actual financial debt, and how does net debt compare to operating cash flow?
- ?How has the 5-year earnings CAGR of 22.5% tracked against capital employed — is return on capital improving or diluting as the debt base grows?
- ?At a forward PE of 51.3, what revenue and margin trajectory is implied, and how does that compare to VIJAYA's own historical growth rate of 21–22% per year?
- ?The stock is near its 52-week high after a 31% 3-month move — what proportion of the current price reflects earnings re-rating versus multiple expansion?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| VIJAYA | Vijaya Diagnostic Centre Ltd.You're viewing | 80.2 | — | 57 |
| Industry avg | across 5 peers | 46.9 | +11.8% | 37 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | — | 54 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.3 | — | 50 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 64.5 | — | 42 |
| CIPLA | Cipla Ltd. | 29.8 | +11.7% | 24 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 26.7 | +11.8% | 17 |
Technical state
Current price
₹1,329.20
SMA 50
₹1,030.13
SMA 200
₹1,022.69
RSI (14)
76.2 (overbought)
From 52w high
-3.6%
1Y return
+34.6%
3M return
+31.0%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- highRSI at 76.19 is in overbought territory; the stock has gained 31.02% over the past 3 months and 34.59% over 1 year, placing price 29% above both SMA50 (₹1,030) and SMA200 (₹1,023). No resistance levels are identified above the current price of ₹1,329, while the nearest support sits at ₹944 — approximately 29% below current price.
- highDebt-to-equity of 42.22 is anomalously elevated for a diagnostics company (not a bank or NBFC where high leverage is structural); the debt trend is classified as rising, adding to balance-sheet concentration risk.
- mediumTrailing PE of 80.24 is the highest among 6 tracked sector peers (peer range: 26.7 to 72.4); forward PE of 51.34 implies significant earnings-growth expectations are already embedded in the price.
- lowROE data is unavailable for VIJAYA and for 4 of 5 sector peers, limiting like-for-like quality comparison. Only Cipla (11.74%) and Dr. Reddys (11.84%) report ROE in this peer set.
Cross-section contradictions
- Operational persistence is strong — 5-year earnings CAGR of 22.5%, FCF positive in 4 of available years, and a consistency score of 83 — yet D/E of 42.22 with a rising trend indicates that growth has been substantially debt-funded, pulling capital-quality and growth-quality signals in opposite directions.
- The stock is near its 52-week high (only 3.63% off peak) and RSI is at 76.19, yet news flow shows no negative headlines (0 of 8 articles negative) and FY26 revenue growth of 26.6% — the elevated valuation and momentum metrics are accompanied by fundamentally constructive recent data, making the risk/stretch balance harder to read from price action alone.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 25 Jun 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 17 May 2026 · rotates through NIFTY 500 every ~5 days